Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01895660 · ClinicalTrials.gov registry record · Phase 2

Children With Hemiparesis Arm and Hand Movement Project (CHAMP Study)

A Phase 2 study, sponsored by Virginia Polytechnic Institute and State University.

Completed
Registry status
Phase 2
Development phase
124
Enrollment target

NCT01895660: Completed Phase 2 study, sponsored by Virginia Polytechnic Institute and State University.

NCT01895660 is a Phase 2 study that has completed, run by Virginia Polytechnic Institute and State University. The registered enrollment target is 124 participants, roughly in line with the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01895660, a Phase 2 study, has completed, sponsored by Virginia Polytechnic Institute and State University.

COMPLETED
Registry status
Phase 2
Development phase
124 participants
Enrollment target

Study Summary

What is the CHAMP Study? The CHAMP Study is a multisite clinical trial funded by the National Institutes of Health that is comparing the efficacy of alternative therapies for young children with unilateral spastic cerebral palsy (or hemiparetic cerebral palsy). Children who meet study eligibility criteria at one of the three clinical sites (Roanoke, VA; Charlottesville, VA, and Columbus, OH) will be invited to enroll, and their parents will be provided all necessary paperwork along with informed consent documentation. Assignment to one of the alternative therapy conditions will be random. Participation in the study includes assessment of each child prior to treatment, close monitoring of the child's progress during treatment, and post-treatment evaluation at the end of therapy, as well as, 6 and 12 months later. Parents will have an active role in the project, both observing their child during therapy sessions and then engaging in home-based activities that allow the child to practice and extend new motor skills. There will be no charge for the therapy provided. What are the therapies being tested? In the past decade or so, a new form of therapy for children with hemiparetic cerebral palsy was developed and has shown to produce positive changes in individual children and in small clinical trials (e.g., DeLuca, Echols, Ramey, \& Taub, 2003; DeLuca, Echols, Law, \& Ramey, 2006; Case-Smith, DeLuca, Stevenson, \& Ramey, 2012). The therapy is named Constraint-Induced Movement Therapy (CIMT) and refers to a multi-component form of therapy in which the child has the unimpaired or less impaired upper extremity constrained (by a cast or a splint) while also receiving active therapy from a specially trained therapist who shapes new skills and functional activities with the child's more impaired upper extremity. Traditionally, CIMT therapy dosages have been high - often lasting many hours per day, 5 days a week, for 4 consecutive weeks. There are important clinical and scien

Primary Outcome

Functional measurements of arm use

Interventions

  • BEHAVIORAL Variations in Pediatric Constraint-Induced Movement Therapy (P-CIMT) versus usual and customary rehabilitation

Trial Details

FieldValue
Enrollment Target 124 participants
Start Date 2013-07
Est. Completion 2019-12
Phase Phase 2

What the finished NCT01895660 record still lists

NCT01895660 is an interventional study that assigns participants to a tested intervention. The registered 124 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target.

The record links to 0 conditions, and to 1 intervention - of which Variations in Pediatric Constraint-Induced Movement Therapy (P-CIMT) versus usual and customary rehabilitation is the first listed.

NCT01895660 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT01895660 about?

NCT01895660 is a clinical study titled "Children With Hemiparesis Arm and Hand Movement Project (CHAMP Study)". What is the CHAMP Study? The CHAMP Study is a multisite clinical trial funded by the National Institutes of Health that is comparing the efficacy of alternative therapies for young children with unilateral spastic cerebral palsy (or hemiparetic cerebral palsy). Children who meet study eligibility c...

What is the current status of trial NCT01895660?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 124 participants. The study started on 2013-07. Estimated completion is 2019-12.

What interventions are being tested in trial NCT01895660?

The interventions under investigation include: Variations in Pediatric Constraint-Induced Movement Therapy (P-CIMT) versus usual and customary rehabilitation (BEHAVIORAL).

Who is sponsoring clinical trial NCT01895660?

This trial is sponsored by Virginia Polytechnic Institute and State University, which has 104 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT01895660's enrollment target sits among peer trials

124 564th of 2000 higher than 1,437 of 2,000 other Phase 2 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02523014 · 124 participants · Phase 2

    Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas

  • NCT02670707 · 124 participants · Phase 3

    Vinblastine/Prednisone Versus Single Therapy With Cytarabine for Langerhans Cell Histiocytosis (LCH)

  • NCT02830724 · 124 participants · Phase 1

    Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to People With CD70 Expressing Cancers

  • NCT04748809 · 124 participants · NA

    Effect of Anti-inflammatory Diet in Rheumatoid Arthritis

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT01895660, the US trial registry maintained by the National Library of Medicine. NCT01895660 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.